A Study on the Prognostic Factors of Breast Cancer Survival Time Using Bayesian Cox Model

Document Type : Original Article (s)

Authors

1 Professor, Department of Biostatistics and Epidemiology, School of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 PhD Student, Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 MSc Student, Department of Biostatistics, School of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4 Student of Medicine, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Abstract

Background: Breast cancer is one of the common diseases among women with various factors involved in it. The purpose of this study was to investigate the effect of tumor markers, estrogen receptor (ER), human epidermal growth factor receptor 2 (Her2), and Ki67 antigen, and other factors affecting the survival time of patients with breast cancer in Yazd City, Iran, using Bayesian multiple Cox regression analysis.Methods: This was a population-based study of 538 women with breast cancer registered in the clinical database of the Ramezanzade Radiotherapy Center from the April 2005 until March 2012. Comprehensive data on prognostic factors, comorbidity and treatment together with complete follow-up for survival were used to evaluate improvements in mortality. Data was analyzed using R 3.4.2 software. P-value of less than 0.050 was considered as the significance level.Findings: The mean age of patients with breast cancer and the mean survival time were 48.03 ± 11.16 years and 97.64 ± 4.23 months, respectively. Based on Kaplan-Meier method, the 1, 3, 5 and 8-year cumulative survivals in patients with breast cancer were 0.976, 0.898, 0.823, and 0.737, respectively. Bayesian Cox regression analysis showed that surgery [Hazard ratio (HR): 1.631, 95% Prediction interval (PI): 1.102-2.422)], ki67 (HR: 3.260, 95%PI: 1.6308-6.372), stage (HR: 5.620, 95%PI: 4.079-7.731), lymph node (HR: 1.765, 95%PI: 1.127-2.790), and estrogen receptor (HR: 2.033, 95%PI; 2.023-3.354) were significantly related to survival time.Conclusion: According to Bayesian multiple cox regression, stage, Ki67, lymph node, estrogen receptor, and surgery variables have a positive effect on death hazard. By combining Bayesian and semi-parametric methods in survival analysis, in order to use prior information and relaxation of parametric assumption, the model gain more flexibility and robustness against misspecification of the probability model; this gives more valuable results.

Keywords

References

  1. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: Systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2016; 164(4): 244-55.
  2. Kazemi A, Eskandari O, Amin Mohammad M, Nesaee P. A survey on breast cancer status in Kurdistan province on medical geography viewpoint during 2006- 2010. J Health Syst Res 2015; 11(3): 459-72. [In Persian].
  3. Kleinbaum DG, Klein M. Survival Analysis. New York, NY: Springer; 2010. vol. 3.
  4. Ibrahim JG, Chen MH, Sinha D. Criterion-based methods for bayesian model assessment. Stat Sin 2001; 11(2): 419-43.
  5. Dardis C. survMisc: An R package to facilitate survival analysis. Neuro-Oncology 2013; 15: 32-6.
  6. Zhou H, Hanson T. spBayesSurv: Bayesian Modeling and Analysis of Spatially Correlated Survival Data. 2014.
  7. Plummer M,Best N, Cowles K, Vines K. CODA: convergence diagnosis and output analysis for MCMC. R News 2006; 6(1) pp. 7–11.
  8. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox Model. New York, NY: Springer; 2000.
  9. Tazhibi M, Fayaz M, Mokarian F. Detection of prognostic factors in metastatic breast cancer. J Res Med Sci 2013; 18(4): 283-90.
  10. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11(2): 174-83.
  11. Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, et al. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol 2015; 68(10): 839-43.
  12. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1(5): 747-54.
  13. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984; 54(11): 2436-40.
  14. Moslemi D, Gholizadeh Pasha A, Hajian K, Sum S, Pourghasem M, Jahantigh R. Comparison of modified radical mastectomy with breast conservative therapy and radiotherapy in patients with breast cancer. J Babol Univ Med Sci 2012; 14(5): 36-41. [In Persian].
  15. Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: Population based study in 173 797 patients. BMJ 2015; 351.
  16. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109(1): 25-32.
  17. Ren Y, Black DM, Mittendorf EA, Liu P, Li X, Du XL, et al. Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. PLoS One 2014; 9(10): e110281.
  18. Fatemeh Asadzadeh Vostakolaei, Mireille J. M. Broeders, Nematollah Rostami, et al., Age at diagnosis and breast cancer survival in Iran. International Journal of Breast Cancer 2012; 2012: 517976.
  19. Zare N, Khodarahmi S, Rezaianzadeh A. The role of prognostic factors on the survival of breast cancer patients: Bayesian approach. Iran J Epidemiol 2015; 11(3): 23-33. [In Persian].
  20. Fallahzadeh H, Momayyezi M, Akhundzardeini R, Zarezardeini S. Five year survival of women with breast cancer in Yazd. Asian Pac J Cancer Prev 2014; 15(16): 6597-601.
  21. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63(1): 181-7.
  22. Haghighat S, OlfatBakhsh A, Sadjadian A, Mehrdad N, Ansari M, Ebrahimi M, et al. Survival rate and its correlated factors in breast cancer patients referred to Breast Cancer Research Center. Iran J Breast Dis 2013; 6(3): 28-36. [In Persian].
  23. Ibrahim JG, Chen MH, Sinha D. Bayesian survival analysis. New York, NY: Springer; 2004.
  24. Klein JP, van Houwelingen HC, Ibrahim JG, Scheike TH. Handbook of survival analysis. Boca Raton, FL: CRC Press; 2014.
Journal of Isfahan Medical School
Volume 36, Issue 466 - Serial Number 466
January and February 2018
Pages 49-55

Files

History

  • Receive Date: 01 November 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics